VIRMA and cancer: Indeed, our previous observations highlighted frequent VIRMA upregulation in primary TGCTs (which was also confirmed in an independent study analyzing multiple cancer types [22]), with strong VIRMA immunoexpression found in 72.4% of samples and, in particular, in 84.2% of metastatic patient samples [3, 10].